Skip to search formSkip to main contentSkip to account menu

LY 191145

Known as: LY-191145, LY191145 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Vancomycin
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1997
Highly Cited
1997
Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues
LY191145 is an N-alkylated glycopeptide antibiotic (the p-chlorobenzyl derivative of LY264826) with activity against vancomycin… 
Highly Cited
1997
Highly Cited
1997
Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices?
Highly Cited
1996
Highly Cited
1996
Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic
LY191145 is a p-chlorobenzyl derivative of LY264826 (A82846B) with activity against both vancomycin-susceptible and -resistant… 
1996
1996
Erratum: Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria (Antimicrobial Agents and Chemotherapy 39:1 (2585))
1995
1995
Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria
LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by… 
1995
1995
Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots
Bactericidal activities of LY191145, an investigational glycopeptide, and vancomycin against Staphylococcus aureus were evaluated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)